Challenges and opportunities in mRNA vaccine development against bacteria
Top Cited Papers
- 29 July 2025
- journal article
- review article
- Published by Springer Nature in Nature Microbiology
- Vol. 10 (8) , 1816-1828
Abstract
The global surge in antimicrobial resistance presents a critical threat to public health, emphasizing the urgent need for the development of new and more effective bacterial vaccines. Since the success of mRNA vaccines during the COVID-19 pandemic, this vaccine strategy has rapidly advanced, with most efforts focused on cancer immunotherapy and targeting viral pathogens. Recently, mRNA vaccines have entered the early phases of clinical development for bacterial diseases. However, bacteria present greater biological complexity compared with viruses, posing additional challenges for vaccine design, such as antigen selection, immune response and mRNA construct design. Here, we discuss critical aspects in the development of bacterial mRNA vaccines, from antigen selection to construct design. We also highlight the current preclinical landscape and discuss remaining translational challenges and future potential for mRNA vaccines against bacterial infections.Keywords
This publication has 134 references indexed in Scilit:
- Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domainNature Immunology, 2003
- Hide and Seek in the PeptidomeScience, 2003
- Induction of Vigorous Helper and Cytotoxic T Cell as well as B Cell Responses by Dendritic Cells Expressing a Modified Antigen Targeting Receptor-Mediated Internalization PathwayThe Journal of Immunology, 2000
- Reverse vaccinologyCurrent Opinion in Microbiology, 2000
- DNA Vaccination against Tuberculosis: Expression of a Ubiquitin-Conjugated Tuberculosis Protein Enhances Antimycobacterial ImmunityInfection and Immunity, 2000
- Codon Optimization Effect on Translational Efficiency of DNA Vaccine in Mammalian Cells: Analysis of Plasmid DNA Encoding a CTL Epitope Derived from MicroorganismsBiochemical and Biophysical Research Communications, 1999
- Identification of LFA-1 as a Candidate Autoantigen in Treatment-Resistant Lyme ArthritisScience, 1998
- Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens.Proceedings of the National Academy of Sciences, 1995
- Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cellsThe Journal of Immunology, 1995
- Intracellular transport of class II MHC molecules directed by invariant chainNature, 1990